



DISA Limited  
(Company Registration No. 197501110N)  
(Incorporated in the Republic of Singapore)  
("Company" and together with its subsidiaries, the "Group")

## NEWS RELEASE:

### **DIGITAL LIFE LINE PTE. LTD., A SUBSIDIARY OF DISA DIGITAL SAFETY PTE. LTD. SECURED NEW FUND FROM INVESTORS AND ITS EXISTING SHAREHOLDERS FOR AN AGGREGATE AMOUNT OF UP TO S\$4 MILLION BASED ON A PRE-MONEY VALUATION OF 100% OF DLL OF S\$20 MILLION**

**SINGAPORE – July 4, 2022** — DiSa Digital Safety Pte. Ltd. ("**DiSa**") is pleased to announce that its subsidiary, Digital Life Line Pte. Ltd. ("**DLL**") has on 1 July 2022, successfully secured a funding of up to S\$4 million from two new investors, namely Isaac Newton Corporation Ltd and SG Global Enterprise Pte. Ltd. (the "**Subscriptions**") as well as from its existing shareholders, namely DiSa, Mr. Chng Weng Wah, Professor Soo Khee Chee and Mr. John Wong Weng Foo (the "**Additional Investments**").

DLL, a subsidiary of DiSa, has, on 1 July 2022, entered into a conditional share subscription agreement with Isaac Newton Corporation Ltd and SG Global Enterprise Pte. Ltd. (the "**Subscription Agreements**"), to subscribe for new preference shares in cash, which represent 7.88% and 2.07% of the total issued and paid-up capital of DLL, post-completion of the Subscriptions, for a total consideration of S\$1.75 million and S\$0.50 million respectively, based on a pre-money valuation of 100% of DLL of S\$20 million agreed to by the parties at arms' length, on a "willing-buyer, willing-seller" basis ("collectively, the "**Subscription Proceeds**").

The Subscription Proceeds will be made in two tranches with first tranche of payment payable upon signing of the Subscription Agreements with S\$0.875 million from Isaac Newton Corporation Ltd and S\$0.25 million from SG Global Enterprise Pte. Ltd. The second tranche payment, with S\$0.875 million from Isaac Newton Corporation Ltd and S\$0.25 million from SG Global Enterprise Pte. Ltd., is subject to DLL's ability to obtain relevant regulatory approvals and successfully secure purchase orders from its customers ("**Second Tranche Payment**").

Isaac Newton Corporation Ltd, a company incorporated in British Virgin Islands, is a member of the Wuthelam Group.

SG Global Enterprise Pte. Ltd. is one of the leading wholesale commodities trading companies in Singapore. International tyre manufacturers and major commodities trading giants are key buyers of their products. Their products are shipped worldwide.

"We are pleased to have completed a successful Series A funding round for DLL," said Professor Soo Khee Chee, Chairman of the Board of DLL, and Inaugural Benjamin Sheares, Professor in Academic Medicine at Duke-NUS Medical School, who is also one of the inventors of the PASPORT enhanced detection platform, "With this new funding, we will continue to leverage on our proprietary on-kit, reader-free signal amplification feature to expand our pipeline of rapid diagnostic kits for other infectious diseases, cancer, and metabolic diseases. We look forward to fostering a vibrant innovation network via internal R&D, existing and future partnerships with universities and industry partners, to further demonstrate the benefits of enhanced detection for point-of-care testing."

DiSa has also, on 1 July 2022, increased its investment in the share capital of DLL by S\$1 million, subscribing for additional new ordinary shares in cash, based on the pre-money valuation as mentioned above. Following the completion of the Subscriptions, DiSa will hold 37.26% of the total

paid-up share capital of DLL. The additional investment of S\$1 million by DiSa is considered a non-discloseable transaction under Rule 1008 of the Catalist Rules and is not expected to have any material impact on the net tangible assets and earnings per share of the Group for the financial year ended 30 June 2022, and was funded by internal resources of the Group.

The existing shareholders of DLL, namely Mr. Chng Weng Wah, Professor Soo Khee Chee and Mr. John Wong Weng Foo have also, on the same day, increased their shareholdings in DLL by S\$0.25 million each, subscribing for additional new ordinary shares in cash, based on the pre-money valuation as mentioned above.

The Subscription Proceeds and the Additional Investments from the existing shareholders of DLL shall be used by DLL for general working capital purposes.

Following the completion of the abovementioned transactions, with effect from 1 July 2022, the composition of shareholders of DLL shall be as follows:

**On signing of Subscription Agreements:**

<b>Name of Shareholder</b>	<b>Shareholding (%)</b>
DiSa	39.21%
Blade Research Pte. Ltd.	32.24%
Chng Weng Wah *	7.19%
Professor Soo Khee Chee	6.32%
John Wong Weng Foo	5.45%
Isaac Newton Corporation Ltd	4.15%
Dr. Chua Lee Kiang, Melvin	3.48%
SG Global Enterprise Pte. Ltd.	1.09%
Dr. Guy Heathers	0.87%
<b>Total</b>	<b>100.00%</b>

**On receipt of Second Tranche Payment:**

<b>Name of Shareholder</b>	<b>Shareholding (%)</b>
DiSa	37.26%
Blade Research Pte. Ltd.	30.64%
Isaac Newton Corporation Ltd	7.88%
Chng Weng Wah *	6.83%
Professor Soo Khee Chee	6.00%
John Wong Weng Foo	5.18%
Dr. Chua Lee Kiang, Melvin	3.31%
SG Global Enterprise Pte. Ltd.	2.07%
Dr. Guy Heathers	0.83%
<b>Total</b>	<b>100.00%</b>


\* Chng Weng Wah is the Managing Director and Chief Executive Officer and substantial shareholder of the Company.

Save as disclosed above, none of the Directors or controlling shareholders of the Company and their respective associates has any interest, direct or indirect, in the above transactions, other than through their respective shareholdings (if any) in the Company.

## DLL BUSINESS UPDATES

DiSa had, through its subsidiary, DLL, signed a tri-party licensing agreement with the National University of Singapore (“NUS”) and Singapore Health Services Pte. Ltd. (“SingHealth”) on 8 December 2021 for the use of their new saliva-based COVID-19 ART technology. This technology was co-developed by inventors from Singapore General Hospital, National Cancer Centre Singapore, Duke-NUS Medical School and NUS.

Since then, DLL has been developing the antigen rapid test (“ART”) kit known as PASPORT™ (Parallel Amplified Saliva rapid POint-of-caRe Test) GOLD and building the on-kit signal amplification feature into a platform, which can be adapted into the existing ART tests in the market for enhanced sensitivity. The clinical validation study for PASPORT™ GOLD is underway, with ongoing applications for regulatory approvals, in addition to the CE-IVD (In-Vitro Diagnostic) mark under the IVD Directive (98/79/EC) that was obtained on 19 May 2022.



“We are pleased to see that our exclusive licensee, DLL has been successful in securing the funding which would help to bring our IP (Intellectual Property) forward and together we hope to make an impact to the healthcare industry.” said Dr. David Wang, Director of the Centre for Technology Development at Duke-NUS.

DLL is positioned as a MedTech company with a proprietary on-kit amplification platform to seamlessly enhance the detection sensitivity of existing and future ART kits, in both single and multiple channel formats. This expands on its rapid success with PASPORT™ GOLD for SARS-CoV-2 and allows DLL to work with global partners to offer convenient, enhanced detection for a wide range of conditions such as infectious diseases (Hepatitis B, Influenza, Dengue), cardiac injury and cancer. By enhancing the detection sensitivity of ART, the platform will facilitate the transformation of diagnostic tests from the centralized lab testing format (that requires specialized equipment and personnel) to rapid point-of-care diagnostic settings, hereby allowing for earlier disease intervention and convenient monitoring.

## BY ORDER OF THE BOARD

Chng Weng Wah  
Managing Director and Chief Executive Officer  
4 July 2022

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited ("**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr. Ong Hwee Li (Registered Professional, SAC Capital Private Limited)*

*Address: 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.*

*Telephone number: +65 6232 3210*

### **About Digital Life Line Pte. Ltd.**

DLL, a subsidiary of DiSa Digital Safety Pte. Ltd., is a healthcare digitalization company that aims to transform the field of point-of-care testing by leveraging its proprietary on-kit signal amplification platform to enhance the detection sensitivity of rapid diagnostic kits, as well as an ecosystem of scalable, serialized diagnostics to facilitate result tracing and reporting. We are focusing on the manufacturing and distribution of reader-free, low-cost signal amplification tools that can be seamlessly adapted to existing and future antigen rapid test (ART) kits for the healthcare industry and at-home testing.

PASPORT™ GOLD SARS-CoV-2 ART kit has been certified as a CE-IVD device under the In-Vitro Diagnostics Directive (IVDD 98/79/EC) on 19 May 2022.

More information is available at <http://www.digital-lifeline.com>.

### **About DiSa Digital Safety Pte. Ltd.**

DiSa, a wholly-owned subsidiary of DISA Limited, is a Singapore-based technology solution provider that specializes in research and development of cutting-edge digital security solution ("**DiSa Asset Protection System**"). With its single scan technology and seamless integration, DiSa has been able to provide item level tracking and data with no disruption to the sales process. This technology is now protecting products and categories previously unachievable with traditional serialization methods, saving millions of dollars in prevented returns.

DiSa entered the US market in 2014 launching its Smart Solutions within the largest retailer in the world with a limited store test. After rigorous testing by the Loss Prevention Research Council, USA, DiSa rolled out its Smart Solutions nationwide in 2017.

### **About DISA Limited**

DISA Limited (SGX: 532), is a publicly-traded company on the Singapore Catalist Stock Exchange. More information is available at <http://www.digital-safety.com>.